Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

PURPOSE: Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has demonstrated systemic efficacy and intracranial activity in various stages of HER2+breast cancer. NALA was a phase III randomized trial that assessed the efficacy and safety of neratinib+capecitabine (N+C) against lapatinib+c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Ming Shen, Feng, Yin Hsun, Chen, Shang Wen, Masuda, Norikazu, Yau, Thomas, Chen, Shou Tung, Lu, Yen Shen, Yap, Yoon Sim, Ang, Peter C. S., Chu, Sung Chao, Kwong, Ava, Lee, Keun Seok, Ow, Samuel, Kim, Sung Bae, Lin, Johnson, Chung, Hyun Cheol, Ngan, Roger, Kok, Victor C., Rau, Kun Ming, Sangai, Takafumi, Ng, Ting Ying, Tseng, Ling Ming, Bryce, Richard, Bebchuk, Judith, Chen, Mei Chieh, Hou, Ming Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505315/
https://www.ncbi.nlm.nih.gov/pubmed/34553296
http://dx.doi.org/10.1007/s10549-021-06313-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505315/
https://www.ncbi.nlm.nih.gov/pubmed/34553296
http://dx.doi.org/10.1007/s10549-021-06313-5

Ejemplares similares